Main contributions to science

Full list (~100) available at https://scholar.google.com/citations?user=NOJgXU0AAAAJ

1. Santos MF, Rappa G, Karbanová DP, Cirrincione G, Carbone D, Manna D, Aalam F, Wang D, Vanier C, Corbeil D, Lorico A HIV-1-induced nuclear invaginations mediated by VAP-A, ORP3, and Rab7 complex explain infection of activated T cells: A novel targetable pathway. Nature Comm. 2023. 14:4588. IMPACT FACTOR=16.6. Altmetric Index 616 - 99th percentile (ranked 436th) of the 204,742 tracked articles of a similar age in all journals.

2. Karbanová J, Deniz IA, Wilsch-Bräuninger M, de Sousa Couto RA, Fargeas CA, Santos MF, Lorico A (co-senior author), Corbeil D. Extracellular lipidosomes containing lipid droplets and mitochondria are released during melanoma cell division. Cell Commun Signal. 2024 Jan 19; 22(1):57. PMID: 38243233.

3. Arena GO, Forte S, Abdouh M, Vanier C, Corbeil D, Lorico A. Horizontal transfer of malignant traits and the involvement of extracellular vesicles in metastasis. Cells 2023 Jun 6;12(12):1566. PMID: 37371036.

4. Santos MF, Rappa G, Fontana S, Karbanová J, Aalam F, Tai D, Li Z, Pucci M, Alessandro R, Morimoto C, Corbeil D, Lorico A. Anti-Human CD9 Fab fragment antibody blocks the extracellular vesicle-mediated increase in malignancy of colon cancer cells. Cells 2022 11:2474.

5. Puglisi C, Giuffrida R, Borzì G, Illari S, Caronia F P, Di Mattia P, Colarossi C, Ferini G, Martorana E, Sette G, Eramo A, Lorico A, Di Grazia A, Forte S.

6. Ex-vivo irradiation of lung cancer stem cells identifies the lowest therapeutic dose needed for tumor growth arrest and mass reduction in vivo. Frontiers in Onc. 2022 12:837400.

7. Santos MF, Rappa G, Karbanová J, Fontana S, Di Bella MA, Pope MR, Parrino B,  Cascioferro SM, Vistoli G, Diana P, Cirrincione G, Arena GO, Woo G, Huang K, Huynh T, Moschetti M, Alessandro R, Corbeil D, Lorico A. Itraconazole inhibits nuclear delivery of extracellular vesicle cargo by disrupting the entry of late endosomes into the nucleoplasmic reticulum. J. Extracell. Ves. 2021 10:e12132. IMPACT FACTOR = 25.8.

8. Fargeas CA, Lorico A, Corbeil D. Commentary: “Could We Address the Interplay Between CD133, Wnt/β-Catenin, and TERT Signaling Pathways as a Potential Target for Glioblastoma Therapy?” Frontiers in Onc. 2021 11:712358. IMPACT FACTOR = 5.7

9. Lorico A, Lorico-Rappa M, Karbanová J, Corbeil D, Pizzorno G. CD9, a tetraspanin target for cancer therapy? Exp Biol Med. 2021 246(9):1121-1138. IMPACT FACTOR = 3.1.

10. Corbeil D, Lorico A. Chapter 3 - Exosomes, microvesicles, and their friends in solid tumors. In: Exosomes, a Clinical Compendium (Editor(s): Lawrence Edelstein, John Smythies, Peter Quesenberry, Denis Noble), 2020. Academic Press, Pages 39-80.

11. Corbeil D, Santos MF, Karbanová J, Kurth T, Rappa G, Lorico A. Uptake and fate of extracellular membrane vesicles: nucleoplasmic reticulum-associated late endosomes as a new gate to intercellular communication. Cells 2020 Aug 21;9(9):1931. IMPACT FACTOR = 6.7.

12. Raimondo S, Giavaresi G, Lorico A, Alessandro R. Extracellular vesicles as biological shuttles for targeted therapies. Int J Mol Sci. 2019 Apr 15;20(8).  IMPACT FACTOR = 3.9

13. Santos MF, Rappa G, Karbanová J, Vanier C, Morimoto C, Corbeil D, Lorico A. Anti-human CD9 antibody Fab fragment impairs the internalization of extracellular vesicles and the nuclear transfer of their cargo proteins. J Cell Mol Med. 2019 Jun; 23(6):4408-4421. IMPACT FACTOR = 4.5

14. Rappa G, Puglisi C, Santos MF, Forte S, Memeo L, Lorico A. Extracellular vesicles from thyroid carcinoma. Int J Mol Sci. 2019 Mar 5;20(5). IMPACT FACTOR = 3.9

15. Osti D, Del Bene M (Co-first authors), Rappa G, Santos MF, Matafora V, Richichi C, Faletti S, Beznoussenko G, Mironov A, Bachi A, Fornasari L, Bongetta, D, Gaetani P, Di Meco F, Lorico A (Co-senior author), Pelicci G. Clinical significance of extracellular vesicles in plasma from glioblastoma patients. Clinical Cancer Res. 2019 25(1):266-276. PMID:30287549. IMPACT FACTOR = 10.2

16. Santos MF, Rappa G, Karbanova J, Kurth T, Corbeil D, Lorico A. VAMP-associated protein-A and oxysterol-binding protein–related protein 3 promote the entry of late endosomes into the nucleoplasmic reticulum J Biol Chem. 2018 293(36):13834 –13848. IMPACT FACTOR = 4.1

17. Lorico A, Rappa G, Corbeil D, Le TT. Observation-driven inquiry: Raman spectroscopic imaging illuminates cancer lipid metabolism. Stem Cell Investigation 2017 May 26;4:42. PMID: 28607916; IMPACT FACTOR = 2

18. Karbanová J, Lorico A, Bornhäuser M, Corbeil D, Fargeas CA. Prominin-1/CD133: lipid raft association, detergent resistance, and immunodetection. Stem Cells Transl Med. 2018 Feb;7(2):155-160. IMPACT FACTOR = 4.7

19. Chao OS, Chang T, Di Bella MA, Alessandro, R, Anzanello F, Rappa G, Goodman OB, Lorico, A. The HDAC6 inhibitor tubacin induces release of CD133+ extracellular vesicles from cancer cells. J. Cell. Biochemistry 2017 Dec;118(12):4414-4424. PMID: 28452069. IMPACT FACTOR = 3.1

20. Rappa G, Fargeas CA, Le TT, Corbeil D, Lorico A. An intriguing relationship between lipid droplets, cholesterol-binding protein CD133 and Wnt/beta-catenin signaling pathway in carcinogenesis. Stem Cells 2015 33:1366-1370. IMPACT FACTOR = 7.0

21. Rappa G, Green TM, Lorico A. The nuclear pool of tetraspanin CD9 contributes to mitotic processes in human breast carcinoma. Mol Cancer Res. 2014 12:1840-1850. IMPACT FACTOR = 5.0

22. Rappa G, Mercapide J, Anzanello F, Pope RM, Lorico A. Biochemical and biological characterization of exosomes containing prominin-1/CD133. Mol Cancer 2013 12:62. IMPACT FACTOR = 6.2

23. Rappa G, Mercapide J, Anzanello F, Le TT, Johlfs MG, Fiscus RR, Wilsch-Bräuninger M, Corbeil D, Lorico A. Wnt interaction and extracellular release of prominin-1/CD133 in human malignant melanoma cells. Exp Cell Res. 2013 319:810-819. IMPACT FACTOR = 3.2

24. Lorico A, Mercapide J, Rappa G. Prominin-1 (CD133) and metastatic melanoma: current knowledge and therapeutic perspectives. Adv Exp Med Biol. 2013 777:197-211. IMPACT FACTOR = 2.0

25. Rappa G, Mercapide J, Lorico A. Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am J Pathol. 2012 180:2504-2515. IMPACT FACTOR = 4.8

26. Mercapide J, Rappa G, Lorico A. The intrinsic fusogenicity of glioma cells as a factor of transformation and progression in the tumor microenvironment. Int J Cancer 2012 131:334-343. IMPACT FACTOR = 6.5

27. Mercapide J, Anzanello F, Rappa G, Lorico A. Relationship between tumor cell invasiveness and polyploidization. PLoS One 2012 7:e53364. IMPACT FACTOR = 3.0

28. Rappa G, Anzanello F, Lorico A. Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells. Cancer Chemother Pharmacol. 2011 67:919-926. IMPACT FACTOR = 3.0

29. Rappa G, Lorico A. Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line. Exp Cell Res. 2010 316:1576-1586. IMPACT FACTOR = 3.2

30. Mercapide J, Rappa G, Anzanello F, King J, Fodstad O, Lorico A. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. Int J Cancer 2010 126:1206-1215. IMPACT FACTOR = 6.5

31. Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, Ju J, Fodstad O, Lorico A. Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res 2008 314:2110-2122. IMPACT FACTOR = 3.2

32. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008 26:3008-3017. IMPACT FACTOR = 7.0

33. Lorico A, Mercapide J, Solodushko V, Alexeyev M, Fodstad O, Rappa G. Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma. Cancer Gene Ther. 2008 15:605-615. IMPACT FACTOR = 3.7

34. Rappa G, Anzanello F, Alexeyev M, Fodstad O Lorico, A. Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease. Eur J Haematol. 2007 78:440-448. IMPACT FACTOR = 2.7

35. Lorico A, Bratbak D, Meyer J, Kunke D, Krauss S, Plott WE, Solodushko V, Baum C, Fodstad O, Rappa G. Gamma-glutamylcysteine synthetase and L-buthionine-(S,R)-sulfoximine: a new selection strategy for gene-transduced neural and hematopoietic stem/progenitor cells. Hum Gene Ther. 2005 16:711-724. IMPACT FACTOR = 4.1

36. Rappa G, Kunke D, Holter J, Diep DB, Meyer J, Baum C, Fodstad O, Krauss S, Lorico A. Efficient expansion and gene transduction of mouse neural stem/progenitor cells on recombinant fibronectin. Neuroscience 2004 124:823-830. IMPACT FACTOR = 3.0

37. Rappa G, Gamcsik MP, Mitina RL, Baum C, Fodstad O, Lorico A. Retroviral transfer of MRP1 and gamma-glutamyl cysteine synthetase modulates cell sensitivity to L-buthionine-S,R-sulphoximine (BSO): new rationale for the use of BSO in cancer therapy. Eur J Cancer 2003 39:120-128. IMPACT FACTOR = 5.4

38. Rappa G, Lorico A, Hildinger M, Fodstad O, Baum C. Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents. Hum Gene Ther. 2001 12:1785-1796. IMPACT FACTOR = 4.1

39. Rappa G, Finch RA, Sartorelli AC, Lorico A. New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models. Biochem Pharmacol. 1999 58:557-562. IMPACT FACTOR = 5.0

40. Rappa G, Lorico A, Liu MC, Kruh GD, Cory AH, Cory JG, Sartorelli AC. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol. 1997 54: 649-655. IMPACT FACTOR = 5.0.

41. Rappa G, Lorico A, Flavell RA, Sartorelli AC. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res. 1997 57:5232-5237. IMPACT FACTOR = 9.3

42. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res. 1997 57:5238-5242. IMPACT FACTOR = 9.3

43. Lorico A, Rappa G, Flavell RA, Sartorelli AC. Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res. 1996 56:5351-5355. IMPACT FACTOR = 9.3

44. Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandes DJ, Germino JF, Sartorelli AC. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Cancer Res. 1995 55:4352-4360. IMPACT FACTOR = 9.3.

45. Rappa G, Lorico A, Sartorelli AC. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Cancer Res. 1993 53:5487-5493. IMPACT FACTOR = 5.3

46. Lorico A, Long BH. Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II. Eur J Cancer 1993 29A:1985-1991. IMPACT FACTOR = 5.4

47. Rappa G, Lorico A, Sartorelli, AC. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs. Cancer Res. 1992 52:2782-2790. IMPACT FACTOR = 9.3

48. Rappa G, Lorico A, Sartorelli AC. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). Int J Cancer 1992 51:780-787. IMPACT FACTOR = 6.5

49. Lorico A, Rappa G, Sartorelli AC. Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells. Int J Cancer 1992 52:903-909. IMPACT FACTOR = 6.5

50. Erba E, Sen S, Lorico A, D'Incalci M. Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin. Eur J Cancer 1992 28:66-71. IMPACT FACTOR = 5.4

51. Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. 1991 51:5275-5283. IMPACT FACTOR = 9.3

52. Rappa G, Lorico A, Sartorelli AC. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II. Cancer Res. 1990 50:6723-6730. IMPACT FACTOR = 5.3

53. Lorico A, Boiocchi M, Rappa G, Sen S, Erba E, D'Incalci M. Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate. Int J Cancer 1990 45:156-162. IMPACT FACTOR = 6.5

54. Lorico A, Toffoli G, Boiocchi M, Erba E, Broggini M, Rappa G, D'Incalci M. Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid. Cancer Res. 1988 48:2036-2041. IMPACT FACTOR = 9.3

55. Lorico A, Masturzo P, Villa S, Salmona M, Semeraro N, de Gaetano G. Gentisic acid: an aspirin metabolite with multiple effects on human blood polymorphonuclear leukocytes. Biochem Pharmacol. 1986 35:2443-2445. IMPACT FACTOR = 5.0